- Country: Belgium
- Summary: Framework Agreement Parenteral Cytostatics
- BET Ref No: 121519292
- Deadline: 18 Aug 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: 409240-2025
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Raamovereenkomst parenterale cytostatica
Carboplatine
Cisplatine
Oxaliplatine
Bendamustine
Methotrexate 5mg/2ml
Azacitidine 100mg
Cytarabine 100mg/5ml
Fluorouracil
Gemcitabine
Pemetrexed
Doxorubicine
Doxorubicine (gepegyleerd)
Epirubicine
Irinotecan 300mg/15ml
Topotecan
Etoposide
Vinorelbine
Cabazitaxel
Docetaxel
Paclitaxel 30mg/5ml en 300mg/50ml
Thiotepa
Trabectedine
Eribuline
Rituximab
Trastuzumab
Bevacizumab
Bortezomib
Folinezuur
Fulvestrant
Methotrexate 1g/40ml
Methotrexate 5g/50ml
Azacitidine 150mg
Paclitaxel 600mg/100ml
Cytarabine 2g/20ml
Irinotecan 1000mg/50ml
Doc Title: Raamovereenkomst parenterale cytostatica
Contract Type: supplies - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINFramework Agreement Parenteral Cytostatics - Belgium Tender
The UNIVERSITY HOSPITAL BRUSSELS, a Government sector organization in Belgium, has announced a new tender for Framework Agreement Parenteral Cytostatics. This tender is published on BelgiumTenders under BET Ref No: 121519292 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-08-18.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
